BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26095605)

  • 1. Precursor States of Brain Tumor Initiating Cell Lines Are Predictive of Survival in Xenografts and Associated with Glioblastoma Subtypes.
    Cusulin C; Chesnelong C; Bose P; Bilenky M; Kopciuk K; Chan JA; Cairncross JG; Jones SJ; Marra MA; Luchman HA; Weiss S
    Stem Cell Reports; 2015 Jul; 5(1):1-9. PubMed ID: 26095605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors.
    Davis B; Shen Y; Poon CC; Luchman HA; Stechishin OD; Pontifex CS; Wu W; Kelly JJ; Blough MD;
    Neuro Oncol; 2016 Mar; 18(3):350-60. PubMed ID: 26245525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme.
    Broadley KW; Hunn MK; Farrand KJ; Price KM; Grasso C; Miller RJ; Hermans IF; McConnell MJ
    Stem Cells; 2011 Mar; 29(3):452-61. PubMed ID: 21425408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments.
    Shen Y; Grisdale CJ; Islam SA; Bose P; Lever J; Zhao EY; Grinshtein N; Ma Y; Mungall AJ; Moore RA; Lun X; Senger DL; Robbins SM; Wang AY; MacIsaac JL; Kobor MS; Luchman HA; Weiss S; Chan JA; Blough MD; Kaplan DR; Cairncross JG; Marra MA; Jones SJM
    Proc Natl Acad Sci U S A; 2019 Sep; 116(38):19098-19108. PubMed ID: 31471491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells.
    Rowse AL; Gibson SA; Meares GP; Rajbhandari R; Nozell SE; Dees KJ; Hjelmeland AB; McFarland BC; Benveniste EN
    J Neurooncol; 2017 Apr; 132(2):219-229. PubMed ID: 28181105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reactive species balance via GTP cyclohydrolase I regulates glioblastoma growth and tumor initiating cell maintenance.
    Tran AN; Walker K; Harrison DG; Chen W; Mobley J; Hocevar L; Hackney JR; Sedaka RS; Pollock JS; Goldberg MS; Hambardzumyan D; Cooper SJ; Gillespie Y; Hjelmeland AB
    Neuro Oncol; 2018 Jul; 20(8):1055-1067. PubMed ID: 29409010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment.
    Tejero R; Huang Y; Katsyv I; Kluge M; Lin JY; Tome-Garcia J; Daviaud N; Wang Y; Zhang B; Tsankova NM; Friedel CC; Zou H; Friedel RH
    EBioMedicine; 2019 Apr; 42():252-269. PubMed ID: 30952620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation.
    Wurdak H; Zhu S; Romero A; Lorger M; Watson J; Chiang CY; Zhang J; Natu VS; Lairson LL; Walker JR; Trussell CM; Harsh GR; Vogel H; Felding-Habermann B; Orth AP; Miraglia LJ; Rines DR; Skirboll SL; Schultz PG
    Cell Stem Cell; 2010 Jan; 6(1):37-47. PubMed ID: 20085741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models.
    Teng J; da Hora CC; Kantar RS; Nakano I; Wakimoto H; Batchelor TT; Chiocca EA; Badr CE; Tannous BA
    Neuro Oncol; 2017 Jun; 19(6):820-832. PubMed ID: 28062830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple Subsets of Brain Tumor Initiating Cells Coexist in Glioblastoma.
    Rennert RC; Achrol AS; Januszyk M; Kahn SA; Liu TT; Liu Y; Sahoo D; Rodrigues M; Maan ZN; Wong VW; Cheshier SH; Chang SD; Steinberg GK; Harsh GR; Gurtner GC
    Stem Cells; 2016 Jun; 34(6):1702-7. PubMed ID: 26991945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ING5 activity in self-renewal of glioblastoma stem cells via calcium and follicle stimulating hormone pathways.
    Wang F; Wang AY; Chesnelong C; Yang Y; Nabbi A; Thalappilly S; Alekseev V; Riabowol K
    Oncogene; 2018 Jan; 37(3):286-301. PubMed ID: 28925404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADAM-9 is a novel mediator of tenascin-C-stimulated invasiveness of brain tumor-initiating cells.
    Sarkar S; Zemp FJ; Senger D; Robbins SM; Yong VW
    Neuro Oncol; 2015 Aug; 17(8):1095-105. PubMed ID: 25646025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EPH Profiling of BTIC Populations in Glioblastoma Multiforme Using CyTOF.
    Hu AX; Adams JJ; Vora P; Qazi M; Singh SK; Moffat J; Sidhu SS
    Methods Mol Biol; 2019; 1869():155-168. PubMed ID: 30324522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.
    Zemp FJ; Lun X; McKenzie BA; Zhou H; Maxwell L; Sun B; Kelly JJ; Stechishin O; Luchman A; Weiss S; Cairncross JG; Hamilton MG; Rabinovich BA; Rahman MM; Mohamed MR; Smallwood S; Senger DL; Bell J; McFadden G; Forsyth PA
    Neuro Oncol; 2013 Jul; 15(7):904-20. PubMed ID: 23585629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid metabolism enzyme ACSVL3 supports glioblastoma stem cell maintenance and tumorigenicity.
    Sun P; Xia S; Lal B; Shi X; Yang KS; Watkins PA; Laterra J
    BMC Cancer; 2014 Jun; 14():401. PubMed ID: 24893952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal stem cells from human fat engineered to secrete BMP4 are nononcogenic, suppress brain cancer, and prolong survival.
    Li Q; Wijesekera O; Salas SJ; Wang JY; Zhu M; Aprhys C; Chaichana KL; Chesler DA; Zhang H; Smith CL; Guerrero-Cazares H; Levchenko A; Quinones-Hinojosa A
    Clin Cancer Res; 2014 May; 20(9):2375-87. PubMed ID: 24789034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
    Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
    Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bmi1 marks intermediate precursors during differentiation of human brain tumor initiating cells.
    Venugopal C; Li N; Wang X; Manoranjan B; Hawkins C; Gunnarsson T; Hollenberg R; Klurfan P; Murty N; Kwiecien J; Farrokhyar F; Provias JP; Wynder C; Singh SK
    Stem Cell Res; 2012 Mar; 8(2):141-53. PubMed ID: 22265735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem cell signature in glioblastoma: therapeutic development for a moving target.
    Nakano I
    J Neurosurg; 2015 Feb; 122(2):324-30. PubMed ID: 25397368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.